Currey H L, Harris J, Mason R M, Woodland J, Beveridge T, Roberts C J, Vere D W, Dixon A S, Davies J, Owen-Smith B
Br Med J. 1974 Sep 28;3(5934):763-6. doi: 10.1136/bmj.3.5934.763.
Azathioprine, cyclophosphamide, and gold have been compared under double-blind conditions in the treatment of relatively early rheumatoid arthritis. Over 18 months the two "immunosuppressive" agents produced clinical improvement comparable to that achieved with gold, and they also facilitated a reduction in the dosage of corticosteroids and retarded radiological joint deterioration. Drug management was easiest with azathioprine. Cyclophosphamide was perhaps marginally the most effective drug but it produced azoospermia in males. If the long-term hazards of malignancy and mutagenesis prove to be acceptable then the anti-proliferative agents provide a useful alternative to gold therapy and can with advantage be given relatively early in the course of rheumatoid arthritis.
在双盲条件下，对硫唑嘌呤、环磷酰胺和金制剂治疗相对早期类风湿关节炎进行了比较。在18个月的时间里，两种“免疫抑制剂”产生的临床改善与金制剂相当，它们还有助于减少皮质类固醇的用量，并延缓关节放射学恶化。硫唑嘌呤的药物管理最为简便。环磷酰胺可能是最有效的药物，但它会导致男性无精子症。如果恶性肿瘤和诱变的长期风险被证明是可以接受的，那么抗增殖药物可作为金制剂治疗的有用替代方案，并且在类风湿关节炎病程中相对早期使用会有优势。
